INVESTOR INTELLIGENCE
Friday, November 20, 2026The Daily Briefing
Biotech news, drug catalysts, and the market moves that matter.
RESEARCH
PAQ Therapeutics Presents First Clinical Data for PT0253, a Selective KRAS G12D Degrader, Showing a Differentiated Safety Profile and Antitumor Activity at ENA 2026
FirstWord Pharma Nov 20
THE NEWSROOM
Latest Intelligence
BusinessFIERCE PHARMA · Nov 20
Fierce Pharma Asia—Ivonescimab’s FDA snub; Pfizer’s in vivo CAR-T deal; China fires scientists in fatal gene trial
Read report
ResearchBIOPHARMA DIVE · Nov 20
Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff
Wall Street analysts rushed to Celldex’s defense following the setback. Elsewhere, Isomorphic Labs cut a cancer-focused deal with Merck and Teva’s research chief accepted a new job.
Read report
ResearchBIOPHARMA DIVE · Nov 20
This week in charts: Biotech investors’ China bets are already paying off
This year, companies built around medicines from China have sped toward acquisitions or IPOs. Meanwhile, Summit is no longer the Wall Street darling it was in 2024.
Read reportTHE NEWSLETTER
Join The Oracle Report (opens in a new tab)The Oracle Report
Daily biotech intelligence on clinical catalysts, regulatory decisions, licensing deals, and investment implications.